ESMO22 Preview 1 – what to watch out for in breast cancer

Review of some of the key trials in breast cancer being showcased in Paris next month

August 22, 2022

Can we predict response to breast cancer therapy?

What can we learn from various breast cancer trials?

December 8, 2021

A twist in the IO tail

Going beyond the obvious conclusion with anti-LAG3 therapy

May 19, 2021

Important learnings from targeted therapies from SABCS

What's worth following on the targeted therapy front in breast cancer? A look pipelines and new indications from SABCS

December 17, 2020

Finding success in hard to treat breast cancers

Post SABCS analysis of a key topic and cancer driver

December 15, 2020

Is pembrolizumab superior to atezolizumab in neoadjuvant TNBC?

A look at the KEYNOTE-522 and neoTRIP clinical trials in neoadjuvant TNBC

December 12, 2019

Highlights and lowlights in HER2+ metastatic breast cancer at SABCS19

A look at tucatinib, margetuximab and trastuzumab deruxtecan in HER2+ advanced MBC

December 11, 2019

Syros CEO Nancy Simonian looks forward to an exciting 2018

Interview with Syros Pharma CEO Dr Nancy Simonian

January 9, 2018

SABCS18 An in-depth review of key breast cancer trials

A rock around the breast cancer clock with cancer immunotherapies and targeted agents from SABCS18

December 7, 2018

SABCS17 Update on CDK4/6 Inhibitors

A look at the latest CDK4/6 inhibitor data including the important phase 3 trial with ribociclib (MONALEESA-7).

December 6, 2017

Is Tucatinib better than Neratinib in HER2-positive Breast Cancer?

2017 could well turn out to be a good year for HER2+ breast cancer with several new developments ongoing. We take a look...

January 30, 2017

Understanding the Mutational Landscape of Metastatic Breast Cancer

How crowdsourcing data from breast cancer patients may help future clinical R&D

January 24, 2017

Targeting Breast Cancer Stem Cells

Will cancer stem cell therapeutics impact the lives of people with metastatic breast cancer?

January 23, 2017

Challenges and Opportunities in Inflammatory Breast Cancer

SABCS16 expert interview on Inflammatory Breast Cancer with Dr Naoto Ueno from MD Anderson Cancer Center.

January 17, 2017

How circulating tumor DNA could change cancer treatment

SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.

January 16, 2017
Dr Leisha Emens SABCS16

Advances in Breast Cancer Immunotherapy

Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens

January 13, 2017

Still looking for a JPM17 Licensing Deal? How about a First-in-Class Drug for Metastatic Breast Cancer?

First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.

January 12, 2017
The Alamo, San Antonio TX

Emerging Trends from SABCS16 in San Antonio

3 trends from SABCS16 that you may hear more about

December 15, 2016

Promising new agents in development for breast cancer

Five promising new agents in development for the treatment of ER+ or HER2+ or triple negative breast cancer emerge from #SABCS15

December 14, 2015

Checkpoint therapy update in metastatic breast cancer

Adding chemotherapy or an ADC boosts the immunogenic effects prior to checkpoint therapy in metastatic breast cancers

December 11, 2015

Biomarin PARP inhibitor talazoparib shows promise in gBRCA Breast Cancer

Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer

January 9, 2015

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015

SABCS Update on Triple Negative Breast Cancer

In the last post of 2014, it’s time to address some pertinent questions on triple negative breast cancer (TNBC).

December 19, 2014

Do Checkpoint Inhibitors work in Triple Negative Breast Cancer?

There is a lot of interest in checkpoint inhibitors, do they look they will be effective in Triple Negative Breast Cancer?

December 10, 2014

AbbVie’s PARP inhibitor veliparib is highly active in triple negative breast cancer

The first readout from the I-SPY2 neoadjuvant breast cancer trial comes from the veliparib (PARP) arm.

December 13, 2013

What to watch for at San Antonio Breast Cancer Symposium

A preview of some of the landmark trial data emerging from the 2013 San Antonio Breast Cancer Symposium

December 11, 2013